Open AccessThe in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus
Author(s) -
Eric G. Romanowski,
Kathleen A. Yates,
John E. Romanowski,
Robert M Q Shanks,
Regis P. Kowalski
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s340576
Subject(s) - cidofovir , hydroxychloroquine , virology , in vitro , medicine , ec50 , ivermectin , virus , potency , antiviral therapy , pharmacology , covid-19 , biology , biochemistry , disease , chronic hepatitis , veterinary medicine , infectious disease (medical specialty)
Presently, there is no approved antiviral therapy for adenovirus (HAdV) ocular infections. During the COVID-19 pandemic, increased attention has been focused on antiviral treatments. Remdesivir, hydroxychloroquine, ivermectin, and umifenovir (Arbidol) have been touted as potential antiviral treatments for COVID-19. The goal of the current study was to determine whether these potential COVID-19 antivirals produce in vitro antiviral activity against a panel of ocular adenovirus types.